FORGOT YOUR DETAILS?

LINK Healthcare Partners With RIEMSER Pharma For Distribution Rights To Market Tepadina® (thiotepa infusion) in Australia and New Zealand

by / Friday, 27 February 2015 / Published in News

Singapore/Sydney/Auckland/Greifswald: 27 Feb 2015 Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) is pleased to announce signing an exclusive agreement with RIEMSER Pharma GmbH (RIEMSER) of Berlin and Greifswald, Germany for the marketing and distribution of TEPADINA®, thiotepa infusion. TEPADINA® is indicated, in combination with other chemotherapy medicinal products as a conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) and when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients. Link and RIEMSER will collaborate to obtain marketing authority for the product in both countries. Chairman of LINK Healthcare, John Bacon, commented: “We are pleased to be entering into a partnership with RIEMSER Pharma and to be expanding our specialty range of oncology products, especially in the area of stem cell transplantation which we have considerable expertise supporting a niche portfolio of complimentary products.” Professor Dr. Kai Deusch, CEO of RIEMSER Pharma explains: “I am very pleased to start our co-operation with LINK in Australia and New Zealand in the field of stem cell transplantation where Tepadina offers significant benefits to patients in critical situations.” About LINK Healthcare (Australia, New Zealand, Southern Africa, Singapore, Hong Kong & Japan) LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa. LINK provides exceptional regulatory, sales, marketing, customer-service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of ‘medicine that matters.’ LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Antiretroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology. About RIEMSER Pharma GmbH RIEMSER Pharma GmbH is a growing European and globally active specialty pharmaceuticals company which markets, sells and distributes medicinal products for human use in selected therapeutic areas with high unmet medical needs. As part of its strategic growth plan, RIEMSER is expanding its market presence in European key markets and intensifying its international presence through trusted partners. RIEMSER has a strong product pipeline and generates lasting value by way of strategic product purchasing and company acquisition coupled with sophisticated life cycle management. RIEMSER has established itself as a highly skilled European platform for the marketing and sales of specialty pharmaceuticals and is continuously seeking partnering opportunities with innovative pharmaceutical companies seeking to enter particularly the European market with their specialty pharmaceutical products, or intending to extend the life cycles and profitability of their products. FOR FURTHER INFORMATION LINK Healthcare contact: Mr John Bacon Chairman +61 28401 9777 E-Mail: info@linkhealthcare.com.au www.linkhealthcare.co RIEMSER Pharma Press Contact: Claudia Kerber Director of Communication Tel.: +49 30 338427-477 E-Mail: kerber@RIEMSER.com www.RIEMSER.com

TOP